Agilent Technologies Inc vs State Street Technology Select Sector SPDR ETF — how do they compare? Agilent Technologies Inc trades at $172.97 (market cap $48.77B), while State Street Technology Select Sector SPDR ETF trades at $183.45 (market cap $124.76B). The key difference: State Street Technology Select Sector SPDR ETF is far larger — about 2.6× Agilent Technologies Inc's market cap, and Agilent Technologies Inc pays a 0.59% dividend while State Street Technology Select Sector SPDR ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Agilent Technologies Inc for 38 Days and State Street Technology Select Sector SPDR ETF for 50 Days on average.
| A | XLK | |
|---|---|---|
Market Cap | $48.77B | $124.76B |
Volume | 2,900,121 | 15,292,136 |
Sector | Health | Sector/Thematic |
52-Week High | $175.55 | $202.00 |
52-Week Low | $110.24 | $127.49 |
Typical Hold Time | 38 Days | 50 Days |
Enterprise Value | $50.96B | — |
Dividend Yield | 0.59% | — |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $175.55, up 0.89% today, near its 52-week high of $174.77 (Defense World, 2026-09-30). The stock shows strong technical momentum with bullish moving averages and a neutral RSI. Recent earnings beat expectations in Q1 and Q2 2026, with revenue growth projected to $7.4B in 2026. The company continues to launch new products like the NovoStation and Gen5 AI module, driving innovation in life sciences and diagnostics.
Outlook remains positive with 80% analyst buy ratings and a consensus price target of $173.08, though current price exceeds this. Key risks include high valuation multiples (P/E 34.12) and dependence on lab instrument replacement cycles. Upside potential hinges on execution of growth initiatives in China and lab automation, while macroeconomic pressures could temper near-term gains.
XLK trades at $189.15, down 0.67% amid a bearish technical signal. The ETF faces headwinds from interest rate concerns and high concentration in semiconductor stocks, with recent news highlighting risks from its quarterly rebalance limitations. Support levels are at $187 and $184, while resistance sits near $191. The overall sentiment is cautious as investors weigh AI growth potential against macroeconomic pressures.
Outlook remains mixed; AI-driven demand offers long-term growth, but near-term risks include Fed rate hikes and sector concentration. Investors should monitor earnings from underlying holdings and broader tech sector performance for directional cues, with downside protection at key support levels.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Read more on XLK →